Short Review on Dapagliflozin
treat type 2 diabetes. It was produced by Bristol-Myers Squibb in organization with AstraZeneca. Dapagliflozin is a sodium-glucose cotransporter 2(SGLT2) inhibitor. It works by diminishing the measure
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
treat type 2 diabetes. It was produced by Bristol-Myers Squibb in organization with AstraZeneca. Dapagliflozin is a sodium-glucose cotransporter 2(SGLT2) inhibitor. It works by diminishing the measure
both patients and surgeons. Topical anesthesia in the form of a cream (EMLA®, Astrazeneca, Karlskoga,Sweden) containing 2.5% lidocaine and 2.5% prilocaine has been reported as efficient as anesthetic
goal of the AIDPATH project: AIDPATH is composed by 4 companies (Leica, Astrazeneca, Barco and TissueGnostics), 3 hospitals and 5 research institutions in Europe and funded by Marie Curie Actions
cancer patients, they have to be considered preliminary. This research project was supported by AstraZeneca Colombia and Diana Torres by a postdoctoral fellowship from the Alexander von Humboldt Foundation
created a need for safer, more convenient alternative anticoagulants for stroke prevention. Ximelagatran (Exanta™, Astrazeneca) is a novel, oral direct thrombin inhibitor that inhibits the final step in the coagulation
oral agents etoposide (VP-16®, Immunex Corporation) and high-dose tamoxifen (Nolvadex®, AstraZeneca) prompted this Phase II study. Tamoxifen and etoposide may be synergistic in their antitumor effects. Both agents
several key collaborations between South Korean companies and multi-national biopharma firms. Pfizer, AstraZeneca, Bristol-Myers Squibb, Sanofi, Novartis, and Otsuka have all invested heavily in local research and…
specific inhibition of (H+/K+) ATPase in gastric parietal cell. It is marketed by Astrazeneca Co., under the brand name NexiumÃ?® 20 mg and 40 mg as gastro-resistant film
made by Laboratorios Tecnoquímicas S.A., Colombia) and the Reference product (Crestor® made by Laboratorios AstraZeneca) in order to declare the Bioequivalence between both formulations. For this, an open-label
omeprazole (Pfizer Inc., US) relative to the reference marketed Losec® capsule (2x20 mg; AstraZeneca, Sweden; enteric-coated granules in capsule) under fasted conditions. Pharmacokinetic blood sampling was carried
tablet and Splendil® extended release 5 mg tablet (Test formulation and reference formulation from AstraZeneca, Brazil) in 36 volunteers of both sexes. The study was conducted open with randomized three
bioequivalence of a generic quetiapine (Ketipinor ® , Orion Corporation, Finland) and the innovator product (Seroquel ® , AstraZeneca, UK). The study was a randomized, two-way crossover design with a two-week washout
associated with and budesonide 200 mcg Alenia ® from Biosintética Farmacêutica Ltd. and Symbicort ®. AstraZeneca, Brazil) in 27 volunteers patients of both sexes. The study used an open, randomized, 2 period
fumarate (kitapen®) manufactured by Cobalt Pharmaceuticals, Canada/ Arrow Farmacêutica Ltda* (Erowlabs). Seroquel® (quetiapine) from Astrazeneca Brazil was used as reference formulation. The study was conducted open…
tablets formulations, Quetiapine of GPO, Thailand and the reference product, Seroquel of AstraZeneca Pharmaceutical Co., Ltd. in healthy Thai volunteers under fasting conditions was conducted with 7 days wash
orphan drug status, for instance, be granted to novel therapeutics. Here we use one AstraZeneca discovery program to illustrate the challenges and opportunities. Th e inhibition of essential cell-wall
orphan drug status, for instance, be granted to novel therapeutics. Here we use one AstraZeneca discovery program to illustrate the challenges and opportunities. Th e inhibition of essential cell-wall
orphan drug status, for instance, be granted to novel therapeutics. Here we use one AstraZeneca discovery program to illustrate the challenges and opportunities. Th e inhibition of essential cell-wall
both patients and surgeons. Topical anesthesia in the form of a cream (EMLA?, Astrazeneca, Karlskoga,Sweden) containing 2.5% lidocaine and 2.5% prilocaine has been reported as efficient as anesthetic
hormone-related cancers like prostate cancer. Th e current dosage forms of goserelin-acetate - AstraZeneca?s Zoladex ? 3.6 mg or 10.8 mg for treatment periods of one month or three
For authors and organisers
Find the right journal for your paper and submit your manuscript.